Literature DB >> 18650497

The JNK-dependent CaMK pathway restrains the reversion of committed cells during osteoclast differentiation.

Eun-Ju Chang1, Jeongim Ha, Hao Huang, Hyung Joon Kim, Jung Hoon Woo, Youngkyun Lee, Zang Hee Lee, Ju Han Kim, Hong-Hee Kim.   

Abstract

Osteoclastogenesis involves the commitment of macrophage-lineage precursors to tartrate-resistant acid phosphatase-positive (TRAP+) mononuclear pre-osteoclasts (pOCs) and subsequent fusion of pOCs to form multinuclear mature osteoclasts. Despite many studies on osteoclast differentiation, little is known about the signaling mechanisms that specifically mediate the osteoclastic commitment. In this study, we found that inhibition of JNK at the pOC stage provoked reversion of TRAP(+) cells to TRAP(-) cells. The conversion to TRAP(-) cells occurred with concomitant return to the state with higher expression of macrophage antigens, and greater activity of phagocytosis and dendritic-differentiation potential. JNK inhibition at the pOC stage reduced NFATc1 and CaMK levels, and addition of active NFATc1 partially rescued the effect of JNK inhibition. In addition, the level of NFATc1 was decreased by knockdown of CaMK by RNAi and by catalytic inhibition of CaMK, which both caused the reversion of pOCs to macrophages. These data suggest that JNK activity is specifically required for maintaining the committed status during osteoclastogenesis and that the CaMK-NFATc1 pathway is the key element in that specific role of JNK.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650497     DOI: 10.1242/jcs.028217

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  23 in total

1.  2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase.

Authors:  Wei-Ling Chang; Chih-Shiang Chang; Po-Cheng Chiang; Yunn-Fang Ho; Ju-Fang Liu; Kai-Wei Chang; Jih-Hwa Guh
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  SLAT negatively regulates RANKL-induced osteoclast differentiation.

Authors:  Bang Ung Youn; Kabsun Kim; Jung Ha Kim; Jongwon Lee; Jang Bae Moon; Inyoung Kim; Yong-Wook Park; Nacksung Kim
Journal:  Mol Cells       Date:  2013-08-29       Impact factor: 5.034

3.  DMSO regulates osteoclast development in vitro.

Authors:  Justin M Lemieux; Gary Wu; Joseph A Morgan; Melissa A Kacena
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-02-27       Impact factor: 2.416

4.  The role of calcium release activated calcium channels in osteoclast differentiation.

Authors:  Yandong Zhou; Tricia L Lewis; Lisa J Robinson; Kathy M Brundage; Rosana Schafer; Karen H Martin; Harry C Blair; Jonathan Soboloff; John B Barnett
Journal:  J Cell Physiol       Date:  2011-04       Impact factor: 6.384

5.  FOXO1 mediates RANKL-induced osteoclast formation and activity.

Authors:  Yu Wang; Guangyu Dong; Hyeran Helen Jeon; Mohamad Elazizi; Lan B La; Alhassan Hameedaldeen; E Xiao; Chen Tian; Sarah Alsadun; Yongwon Choi; Dana T Graves
Journal:  J Immunol       Date:  2015-02-18       Impact factor: 5.422

6.  TLT-1s, alternative transcripts of triggering receptor expressed on myeloid cell-like transcript-1 (TLT-1), Inhibits the triggering receptor expressed on myeloid cell-2 (TREM-2)-mediated signaling pathway during osteoclastogenesis.

Authors:  Soo-Hyun Yoon; Yong Deok Lee; Jeongim Ha; Youngkyun Lee; Hong-Hee Kim
Journal:  J Biol Chem       Date:  2012-07-03       Impact factor: 5.157

Review 7.  Regulation of Embryonic and Postnatal Development by the CSF-1 Receptor.

Authors:  Violeta Chitu; E Richard Stanley
Journal:  Curr Top Dev Biol       Date:  2016-12-01       Impact factor: 4.897

8.  MKP-1 signaling events are required for early osteoclastogenesis in lineage defined progenitor populations by disrupting RANKL-induced NFATc1 nuclear translocation.

Authors:  Michael S Valerio; Bethany A Herbert; Alfred C Griffin; Zhuang Wan; Elizabeth G Hill; Keith L Kirkwood
Journal:  Bone       Date:  2013-11-20       Impact factor: 4.398

9.  Peroxiredoxin II negatively regulates lipopolysaccharide-induced osteoclast formation and bone loss via JNK and STAT3.

Authors:  Hyojung Park; A Long Sae Mi Noh; Ju-Hee Kang; Jung-Sun Sim; Dong-Seok Lee; Mijung Yim
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

10.  Plasma membrane calcium ATPase regulates bone mass by fine-tuning osteoclast differentiation and survival.

Authors:  Hyung Joon Kim; Vikram Prasad; Seok-Won Hyung; Zang Hee Lee; Sang-Won Lee; Aditi Bhargava; David Pearce; Youngkyun Lee; Hong-Hee Kim
Journal:  J Cell Biol       Date:  2012-12-24       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.